Published in Biochem Biophys Res Commun on June 17, 2010
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood (2011) 1.88
Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis (2011) 1.76
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med (2011) 1.33
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov (2012) 1.33
Targeting AMPK for cancer prevention and treatment. Oncotarget (2015) 1.13
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood (2011) 0.96
Role of AMPK in UVB-induced DNA damage repair and growth control. Oncogene (2012) 0.96
Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care (2012) 0.94
A phase I study of temsirolimus and metformin in advanced solid tumours. Invest New Drugs (2010) 0.93
NUAK2: an emerging acral melanoma oncogene. Oncotarget (2011) 0.90
Inhibition of melanogenesis by the antidiabetic metformin. J Invest Dermatol (2014) 0.85
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Front Oncol (2015) 0.82
Involvement of ER stress and activation of apoptotic pathways in fisetin induced cytotoxicity in human melanoma. Arch Biochem Biophys (2014) 0.81
Statins and Finasteride Use Differentially Modify the Impact of Metformin on Prostate Cancer Incidence in Men with Type 2 Diabetes. Ann Transl Med Epidemiol (2015) 0.80
1,3-Bis(3,5-dichlorophenyl) urea compound 'COH-SR4' inhibits proliferation and activates apoptosis in melanoma. Biochem Pharmacol (2012) 0.79
Metformin and cancer. Rev Diabet Stud (2014) 0.78
Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration. Oncol Lett (2015) 0.76
AICAR induces mitochondrial apoptosis in human osteosarcoma cells through an AMPK-dependent pathway. Int J Oncol (2016) 0.75
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell (2008) 16.72
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem (1995) 7.12
The two TORCs and Akt. Dev Cell (2007) 6.17
The AMP-activated protein kinase pathway--new players upstream and downstream. J Cell Sci (2004) 5.65
The Akt-mTOR tango and its relevance to cancer. Cancer Cell (2005) 5.34
Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology (2003) 5.09
Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58
AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays (2001) 4.07
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85
Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem (2005) 3.74
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A (2005) 2.93
5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem (2005) 2.57
New insight into BRAF mutations in cancer. Curr Opin Genet Dev (2007) 2.40
AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun (2004) 1.95
Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res (2005) 1.57
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol (2008) 1.35
5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF{alpha}-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Mol Cancer Ther (2007) 1.35
Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene (2009) 1.34
Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer (2007) 1.31
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res (2006) 1.31
AMPK and Raptor: matching cell growth to energy supply. Mol Cell (2008) 1.27
Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res (2007) 1.20
Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses. J Biol Chem (2009) 1.14
Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res (2008) 1.13
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer (2008) 1.09
Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res (2008) 0.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol Cell Biol (2005) 1.97
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood (2008) 1.95
Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A (2008) 1.81
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A (2010) 1.75
Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem (2002) 1.72
Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem (2001) 1.71
AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther (2010) 1.66
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood (2012) 1.66
Interferons: mechanisms of action and clinical applications. Curr Opin Oncol (2003) 1.56
Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma (2009) 1.53
Jak family of kinases in cancer. Cancer Metastasis Rev (2003) 1.52
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood (2006) 1.48
MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A (2002) 1.47
Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol (2002) 1.41
Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem (2006) 1.41
Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res (2005) 1.40
Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem (2003) 1.36
Statins in tumor suppression. Cancer Lett (2008) 1.34
Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene (2002) 1.32
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res (2006) 1.31
Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res (2011) 1.29
The interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1. J Biol Chem (2004) 1.29
Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther (2008) 1.28
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood (2013) 1.26
Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget (2011) 1.26
Activation of protein kinase C delta by IFN-gamma. J Immunol (2003) 1.25
Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res (2004) 1.25
The p38 mitogen-activated protein kinase pathway in interferon signal transduction. J Interferon Cytokine Res (2005) 1.23
Role of p38alpha Map kinase in Type I interferon signaling. J Biol Chem (2003) 1.23
Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J Immunol (2008) 1.22
Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem (2008) 1.21
Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals. Mol Cell Biol (2009) 1.21
Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res (2007) 1.20
Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum (2004) 1.19
Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem (2010) 1.17
Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One (2012) 1.17
The PI3' kinase pathway in interferon signaling. J Interferon Cytokine Res (2005) 1.17
Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem (2002) 1.17
Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci U S A (2009) 1.17
Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses. J Biol Chem (2009) 1.14
Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc Natl Acad Sci U S A (2003) 1.14
Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res (2005) 1.13
Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res (2008) 1.13
Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood (2013) 1.13
Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells. J Biol Chem (2010) 1.12
Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma (2008) 1.11
Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide. J Biol Chem (2006) 1.11
Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J Biol Chem (2007) 1.11
Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res (2010) 1.10
Engagement of protein kinase C-theta in interferon signaling in T-cells. J Biol Chem (2004) 1.10
Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells. J Biol Chem (2008) 1.08
Activation of protein kinase C delta by all-trans-retinoic acid. J Biol Chem (2003) 1.06
Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res (2007) 1.06
Mechanisms of type-I interferon signal transduction. J Biochem Mol Biol (2004) 1.04
Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication. J Virol (2006) 1.04
All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br J Haematol (2010) 1.04
8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma. Mol Cancer Ther (2005) 1.04
Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. Proc Natl Acad Sci U S A (2012) 1.03
Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood (2005) 1.03
Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription. Mol Cell Biol (2010) 1.02
Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem (2004) 1.02
Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. J Biol Chem (2008) 1.02
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget (2011) 1.02
HoxA10 regulates transcription of the gene encoding transforming growth factor beta2 (TGFbeta2) in myeloid cells. J Biol Chem (2010) 1.01
Targeting AMPK in the treatment of malignancies. J Cell Biochem (2012) 1.00
CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. Blood (2008) 1.00
Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene (2005) 0.99
p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene (2003) 0.99
Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol (2008) 0.99
Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis. J Biol Chem (2010) 0.99
The schlafen family of proteins and their regulation by interferons. J Interferon Cytokine Res (2013) 0.99
Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma (2009) 0.98
The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis. J Interferon Cytokine Res (2007) 0.98
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem (2011) 0.97
c-Src interacts with and phosphorylates RelA/p65 to promote thrombin-induced ICAM-1 expression in endothelial cells. Am J Physiol Lung Cell Mol Physiol (2006) 0.97
Mechanisms of mRNA translation of interferon stimulated genes. Cytokine (2010) 0.97
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood (2011) 0.96
Role of Stat5 in type I interferon-signaling and transcriptional regulation. Biochem Biophys Res Commun (2003) 0.96
α6β4 integrin, a master regulator of expression of integrins in human keratinocytes. J Biol Chem (2012) 0.95
An overview of the mTOR pathway as a target in cancer therapy. Expert Opin Ther Targets (2012) 0.95
Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. Exp Hematol (2005) 0.94
Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol (2011) 0.93
EVI1 abrogates interferon-alpha response by selectively blocking PML induction. J Biol Chem (2004) 0.93
Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses. Mol Pharmacol (2010) 0.92
Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clin Cancer Res (2014) 0.92
A role for mixed lineage kinases in regulating transcription factor CCAAT/enhancer-binding protein-{beta}-dependent gene expression in response to interferon-{gamma}. J Biol Chem (2005) 0.92
Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood (2004) 0.92
Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun (2004) 0.91
TGF-β/Smad3 activates mammalian target of rapamycin complex-1 to promote collagen production by increasing HIF-1α expression. Am J Physiol Renal Physiol (2013) 0.91
Regulatory effects of programmed cell death 4 (PDCD4) protein in interferon (IFN)-stimulated gene expression and generation of type I IFN responses. Mol Cell Biol (2012) 0.90
Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. J Biol Chem (2012) 0.90
HoxA10 protein regulates transcription of gene encoding fibroblast growth factor 2 (FGF2) in myeloid cells. J Biol Chem (2012) 0.89
Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses. Cancer Biol Ther (2013) 0.89
Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis. J Biol Chem (2011) 0.89
Activation of protein kinase C{eta} by type I interferons. J Biol Chem (2009) 0.88
Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther (2006) 0.88
Interferon-alpha/beta-receptor interactions: a complex story unfolding. Curr Pharm Des (2002) 0.88
Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling. J Biol Chem (2010) 0.87